Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00199862 · ClinicalTrials.gov registry record · NA
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00199862: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00199862 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00199862, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether our drug, 124I-huA33, can safely detect colorectal cancer.
Interventions
- DRUG Iodine-124 labeled humanized A33 (antibody)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-02 |
| Est. Completion | 2025-07-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00199862
The ClinicalTrials.gov registry entry for NCT00199862 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iodine-124 labeled humanized A33 (antibody) is the first listed.
NCT00199862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00199862 about?
NCT00199862 is a clinical study titled "Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer". The purpose of this study is to determine whether our drug, 124I-huA33, can safely detect colorectal cancer.
What is the current status of trial NCT00199862?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2004-02. Estimated completion is 2025-07-02.
What interventions are being tested in trial NCT00199862?
The interventions under investigation include: Iodine-124 labeled humanized A33 (antibody) (DRUG).
Who is sponsoring clinical trial NCT00199862?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.